This is the protocol for a review and there is no abstract. The objectives are as follows:
1. To determine the effect of oral zinc supplementation compared to placebo or no treatment on the incidence of hyperbilirubinemia in neonates during the first week of age.
Comparison will include:
term vs. preterm neonates;
all neonates vs. neonates at risk of hyperbilirubinemia;
low dose (≤ 10 mg) vs. higher dose of the oral zinc;
lesser (< 72 h) vs. greater (≥ 72 h) duration of treatment.
2. To assess the safety of the oral zinc in enrolled neonates.